Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Hot Off the Press: Pfizer Goes After Abbott

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

It's shaping up to be another eventful day in the health care industry. Here at, we'll be following the market reaction to a high-profile Food and Drug Administration approval for Pfizer  (NYSE: PFE  ) , as well as an earnings report from obesity drugmaker Arena Pharmaceuticals  (Nasdaq: ARNA  ) .

Yesterday, Pfizer's rheumatoid arthritis drug tofacitnib, now christened with the brand name Xeljanz, was handed a faster than anticipated approval by the FDA. Widely anticipated to be a blockbuster capable of more than $2 billion in sales, the drug's approval could mark the beginning of an epic battle with Abbott's  (NYSE: ABT  )  Humira, which will soon approach annual sales near the $10 billion mark. Other drugs likely to feel the pinch include Johnson & Johnson's  (NYSE: JNJ  )  top seller, Remicade, as well as Pfizer's own Enbrel.

While Xeljanz might cannibalize some Enbrel revenue in the near term, the net effect should be a positive one. That's because the economics of Enbrel sales are subject to a partnership with Amgen  (Nasdaq: AMGN  ) . Under the co-promotion agreement, which expires in October of next year, the two companies share Enbrel profits in the U.S. and Canada. After expiration, Pfizer's set to receive a smaller royalty for the next three years. While the effect from Xeljanz stealing Enbrel sales might mean shooting their own foot a bit in the near term, bringing Xeljanz to market ahead of the deal's expiration is incredible for the company going forward.

Moving from one lucrative therapeutic area to another potentially lucrative one, obesity drugmaker Arena Pharmaceuticals released quarterly results after yesterday's close. Since its drug Belviq isn't yet commercialized, the results were light on, well, results. The company generated a negligible amount of revenue and posted a slightly lower loss than expected.

While Arena did announce a collaboration agreement in South Korea, the real news yesterday was a sales checkup from rival VIVUS  (Nasdaq: VVUS  ) , whose obesity drug Qsymia hit the market in mid-September. Its weaker-than-expected results, along with discouraging commentary around insurance coverage, sunk all ships in the obesity space. While I didn't find anything too notable to merit a huge reaction in Arena shares today, the hangover from VIVUS' disappointing report could continue in today's session.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2099635, ~/Articles/ArticleHandler.aspx, 10/26/2016 3:49:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,218.89 49.62 0.27%
S&P 500 2,140.46 -2.70 -0.13%
NASD 5,253.69 -29.71 -0.56%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 3:34 PM
ABT $39.99 Down -0.21 -0.51%
Abbott Laboratorie… CAPS Rating: *****
PFE $32.41 Up +0.13 +0.40%
Pfizer CAPS Rating: ****
JNJ $114.80 Up +0.84 +0.73%
Johnson and Johnso… CAPS Rating: ****